FDA Approves New Imaging System to Enhance Cervical Cancer Detection

Publication
Article
OncologyONCOLOGY Vol 22 No 14
Volume 22
Issue 14

BD Diagnostics recently announced that it received US Food and Drug Administration (FDA) Premarket Approval for the BD FocalPoint GS Imaging System.

BD Diagnostics recently announced that it received US Food and Drug Administration (FDA) Premarket Approval for the BD FocalPoint GS Imaging System. This innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath Pap test slides to detect evidence of squamous carcinoma, adenocarcinoma and their usual precursor conditions.

Articles in this issue
The Absent-Minded Professor: An Unusual Complication of Melanoma
The Absent-Minded Professor: An Unusual Complication of Melanoma
Inflammatory Breast Cancer: A Complex Disease
Defining the IBC Phenotype
Acupuncture
Acupuncture
Two Orphan Drug Designations Granted for Reviroc in NHL
NDA Submitted for Trabectedin to Treat Relapsed Ovarian Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
Related Content
Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Viviana Cortiana, MS4;Maduri Balasubramanian, MD;Jade Gambill, BS;Diksha Mahendru, MD;Kennedy Itodo, MD;Chandler H. Park, MD, MS, FACP;Yan Leyfman, MD
August 15th 2025
Article
Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
August 15th 2025
Podcast
A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck

A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck

Omar K. Abughanimeh, MBBS;Nicole A. Shonka, MD;Jane Meza, PhD;Lynette Smith, PhD;Irfan A. Vaziri, MD;Mehmet Sitki Copur, MD;Robin High, MBA;Kimberly Shields, BSN, RN;Holly DeSpiegelaere, BSN, RN;Anne Kessinger, MD;Apar Kishor Ganti, MD, MS
August 15th 2025
Article
Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
August 15th 2025
Podcast
Exercise significantly enhances cancer treatment outcomes, improving survival rates and quality of life for patients with colon cancer who have completed therapy.

New Colon Cancer Data Shows Importance of Exercise Therapy for Survival

Neil M. Iyengar, MD
August 15th 2025
Article
Oncologists explore the considerations of mirvetuximab soravtansine treatment in platinum-resistant ovarian cancer, highlighting its efficacy and the management of ocular AEs.

Highlighting Multidisciplinary Ovarian Cancer Care With Oncologists, Ophthalmologists, and Nurses

ONCOLOGY Staff
August 15th 2025
Article